Sunshine Lake Pharma (SEHK:6887), What Is Behind The Latest Attention?

Recent trading in Sunshine Lake Pharma (SEHK:6887) has drawn fresh attention after the share price moved to HK$39.60, capping a month with mixed short term returns and a stronger performance over the past 3 months.

For context, Sunshine Lake Pharma’s recent 7 day share price return of 8.79% and 90 day gain of 16.47% come after a year to date decline of 11.29% and a 1 year total shareholder return that fell 19.45%, set against much stronger 3 and 5 year total shareholder returns of 72.58% and 150.61% respectively. This suggests short term momentum has picked up while the longer track record remains shaped by earlier gains.

Scan how Sunshine Lake Pharma compares with other pharmaceutical players showing similar momentum and longer track records in our hand picked list of 182 high quality undervalued stocks.

Sunshine Lake Pharma has a long record of strong total returns over 3 and 5 years, yet the recent share price move to HK$39.60 raises a different issue. Are investors now paying too much, or still getting a fair deal?

Preferred Price-to-Sales of 4.9x: Is it justified?

On simple sales based metrics, Sunshine Lake Pharma trades on a P/S ratio of 4.9x, while recent trading has the share price at HK$39.60. That puts the current valuation above the wider Hong Kong Pharmaceuticals industry average yet below a narrower peer group using the same measure.

The P/S ratio compares the company’s market value to its annual revenue, which for Sunshine Lake Pharma is reported at HK$3,952.71m. For a business that is currently loss making, this kind of metric is often used as a rough shortcut when earnings do not yet give a clean picture of profitability.

Relative to direct peers, the stock is described as good value on this preferred multiple, with its 4.9x level below a peer average of 6.1x. That points to the market assigning a lower sales based valuation than similar pharmaceutical groups, even though the firm is still unprofitable and interest payments are not well covered by earnings.

The comparison changes when you widen the lens to the broader Hong Kong Pharmaceuticals industry, where the average P/S ratio is 2.1x. On that basis, Sunshine Lake Pharma trades at a materially richer multiple than the sector, which signals investors are paying a higher price per dollar of sales than for the industry overall.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-Sales of 4.9x (OVERVALUED).

Still, Sunshine Lake Pharma faces clear risks, including ongoing losses on HK$3,952.71m in revenue and interest costs that current earnings do not comfortably cover.

Find out about the key risks to this Sunshine Lake Pharma narrative.

Another View: DCF Puts Sunshine Lake Pharma On A Different Track

The market is valuing Sunshine Lake Pharma at HK$39.60 per share, yet our DCF model points to a future cash flow value of HK$6.87. That gap suggests the stock is priced well above the cash flows the model attributes to it, which raises a simple question: What are investors paying up for?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Sunshine Lake Pharma for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 182 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Curious whether the tone around Sunshine Lake Pharma feels too cautious or not cautious enough? Move quickly, review the underlying data, and weigh the 2 important warning signs.

Looking for more Sunshine Lake Pharma style investment ideas?

If Sunshine Lake Pharma has you thinking harder about valuation and risk, do not stop here. Use the Simply Wall St screener to surface other opportunities that could suit your approach.

• Zero in on value focused candidates that combine quality fundamentals with attractive pricing by scanning the 182 high quality undervalued stocks.
• Prioritise resilience and capital strength by filtering for companies on the list of solid balance sheet and fundamentals (202 results).
• Get ahead of the crowd by reviewing the 620 high quality undiscovered gems before attention and capital move on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com